左西孟旦对急性心衰患者心功能及cTnT, hs-CRP, NT-proBNP水平影响

目的:观察左西孟旦对急性心力衰竭患者心功能及cTnT、hs-CRP、NT-proBNP水平影响。方法:选取在我院就诊的327例急性心力衰竭患者,按照治疗方式不同,分为观察组(常规治疗+左西孟旦)164例和对照组(常规治疗)163例,对比两组用药前及用药后24 h的左心射血分数(LVEF)、每搏输出量(SV)、肌钙蛋白T(cTnT)、超敏C反应蛋白(hs-CRP)和氨基末端B型利钠肽前体(NT-proBNP)水平。结果:治疗前,两组LVEF和SV比较,差异无统计学意义(P0.05)。治疗后观察组LVEF和SV均显著高于治疗前(P0.05);对照组LVEF显著高于治疗前(P0.05),SV与治疗前比较,差异无统计学意义(P0.05)。治疗后观察组LVEF和SV均显著高于对照组(P0.05)。治疗前两组cTnT、hs-CRP、NT-proBNP水平比较,差异无统计学意义(P0.05)。治疗后两组cTnT、hs-CRP、NT-proBNP水平均显著低于治疗前(P0.05)。治疗后观察组cTnT、hs-CRP、NT-proBNP水平显著低于对照组(P0.05)。两组不良反应比较差异无统计学意义(P0.05)。结论:左西孟旦治疗急性心力衰竭可明显增加心肌收缩力,抑制心肌重塑,减轻炎症反应,改善患者预后。

Effect of Levosimendan on Cardiac Function and cTnT, hs-CRP andNT-proBNPLevels in Patients with Acute Heart Failure

Objective:To observe the effect of levosimendan on cardiac function and cTnT, hs-CRP and NT-proBNP levels in patientswith acute heart failure.Methods:327 cases of patients with acute heart failure in our hospital were selected in accordance with thedifferent treatment modalities, 163 patients in the control group were given routine treatment and 164 casesin the observation group weregiven conventional treatment combined with levosimendan. The left heart shot ejection fraction (LVEF), stroke volume (SV), cardiac troponinT (cTnT) and ultra sensitive C reactive protein (hs CRP) and N-terminal pro-B-type natriuretic peptide (NT proBNP) level were detectedbefore treatment and 24 h after treatment and compared between two groups.Results:There was no significant difference in LVEFand SV before treatment between the two groups (P>0.05). After treatment, LVEF and SV level were significantly higher than beforetreatment inthe observation group, (P<0.05); and the LVEF level in control group was significantly higher than before treatment (P<0.05),but SV level was not statistically significant compared with before treatment (P>0.05). After treatment, the LVEF and SV level were significantlyhigher observation group than that of control group (P<0.05). The difference in the level of cTnT, hs-CRP, NT-proBNPwas notstatistically significant before treatment (P>0.05), and after treatment, the levels of cTnT, hs-CRP and NT-proBNP were significantlylower compared with before treatment (P<0.05), and they were significantly lower in the observation group than those of the controlgroup (P<0.05). No significant differences in the rate of adverse reactions between the two groups (P>0.05).Conclusion:Levosimendancan significantly increase myocardial contractility, inhibit myocardial remodeling, reduce the inflammation and improve the prognosis ofpa- tients with acute heart failure.